News

The study namely BOLERO-2 (Breast cancer trials of OraL EveROlimus-2) involved around 700 patients at over 195 sites worldwide. The study included postmenopausal women with ER+HER2- metastatic breast

A wholly subsidiary of Fresenius Kabi Pharmaceuticals, APP Pharma expects to launch extended product line of its current portfolio in next few months. The company will market Levothyroxine

With this acquisition, Swisher Hygiene will use Sanolite’s headquarters to operate its chemical business in the Northeast region. The new regional operating structure allows for more efficient distribution

Chantix is a non-nicotine prescription medicine to help adults 18 and over stop smoking. Pfizer said results from 14 clinical trials involving approximately 7,000 smokers played vital role

Following the completion of an ongoing open-label Phase 1b clinical trial, the company intends to start INNO-206 Phase 2b trial with late-stage soft tissue sarcomas in the second

The company expects to diagnose patients with a medical condition -pain and inflammation of the knee-osteoarthritis. In this study, Ampion is injected into the knees of patients with

Frik Ilac has a core portfolio of original prescription products both in primary care and specialist areas and employs 350 personnel, of which around 260 are medical representatives.

XARELTO, which belongs to a group of medicines called anticoagulants, works by blocking the blood clotting Factor Xa and thereby reduces the tendency of the blood to form

Sorrento Therapeutics will receive a total of $600,000, $300,000 annually for two years as Phase I grant. The company will also receive $1m per year for up to